183 related articles for article (PubMed ID: 24816798)
1. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis.
Zhang T; Zhang DM; Zhao D; Hou XM; Liu XJ; Ling XL; Ma SC
J Mol Histol; 2014 Oct; 45(5):533-40. PubMed ID: 24816798
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer.
Lin Q; Guo L; Lin G; Chen Z; Chen T; Lin J; Zhang B; Gu X
Cancer Epidemiol; 2015 Aug; 39(4):539-44. PubMed ID: 26123318
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review.
Song Y; Li H; Jiang Q; Wu L
Biomarkers; 2024 Mar; 29(2):105-113. PubMed ID: 38376506
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
[TBL] [Abstract][Full Text] [Related]
7. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
10. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density.
Yu TT; Han ZG; Shan L; Tao J; Zhang T; Yuan SF; Shen HL
Asian Pac J Cancer Prev; 2014; 15(1):29-32. PubMed ID: 24528042
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
Liu X; Huang G; Zhang J; Zhang L; Liang Z
PLoS One; 2020; 15(10):e0240321. PubMed ID: 33052949
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer: A systematic review and meta-analysis.
Min SH; Zheng QQ
Medicine (Baltimore); 2021 Nov; 100(47):e27919. PubMed ID: 34964763
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis.
Zhang J; Gu Y; Liu X; Rao X; Huang G; Ouyang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32696952
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma.
Štemberger C; Matušan-Ilijaš K; Avirović M; Bulat-Kardum L; Ivančić A; Jonjić N; Lučin K
Acta Histochem; 2014 Jan; 116(1):222-9. PubMed ID: 23992637
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review.
Luo Z; Wu RR; Lv L; Li P; Zhang LY; Hao QL; Li W
Int J Clin Exp Pathol; 2014; 7(7):3632-46. PubMed ID: 25120740
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
17. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis.
Ren W; Mi D; Yang K; Cao N; Tian J; Li Z; Ma B
Swiss Med Wkly; 2013; 143():w13855. PubMed ID: 24018850
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection.
Sun BS; Li Y; Zhang ZF; You J; Wang CL
Ann Thorac Surg; 2013 Dec; 96(6):1943-51. PubMed ID: 24094519
[TBL] [Abstract][Full Text] [Related]
19. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
